On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Gynecologic Cancer Immunotherapy Guideline Expert Panel, we are pleased to announce the publication of SITC’s Gynecologic Cancer Clinical Practice Guideline (CPG). This manuscript is SITC’s first CPG covering immunotherapy indications for cervical, endometrial, and ovarian cancer, as well as other rare gynecologic cancers.
The treatment landscape in gynecologic cancers is dynamic. In recent years, immune checkpoint inhibitors (ICIs) have become the standard of care for advanced disease in both cervical and endometrial cancer. Moreover, recent phase III trials in endometrial cancer have reported clinically-significant positive data with the use of ICI-based combinations in the first-line setting, further shifting the treatment landscape. While the addition of ICIs has improved outcomes for many patients with gynecologic cancer, in clinical practice their use is nuanced. Certain indications specify PD-L1 expression or mismatch repair (MMR) status, and therefore an understanding of the appropriate biomarker testing for each disease state is critical for clinicians.
The SITC Gynecologic Cancer Immunotherapy Guideline Expert Panel was formed to generate evidence- and consensus-based recommendations to help clinicians navigate the treatment landscape and biomarker testing, along with other topics such as treatment of rare gynecologic subtypes, considerations for special patient populations, and quality of life and patient education considerations. The manuscript, the latest in the ongoing series of SITC Cancer Immunotherapy Guidelines, is available in the Journal for ImmunoTherapy of Cancer (JITC), SITC’s open access, peer-reviewed online journal.